Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Solicits Bids For Levothyroxine Stability Testing

This article was originally published in The Pink Sheet Daily

Executive Summary

Some manufacturers have been unable to demonstrate that their products have a two-year shelf life, the agency said.

You may also be interested in...



Levothyroxine Potency Specs Should Be Narrower, Joint FDA Advisory Cmte. Says

The potency specifications for the troubled levothyroxine should be narrowed from 90-110% to 95-105%, committee members recommend.

Levothyroxine Potency Specs Should Be Narrower, Joint FDA Advisory Cmte. Says

The potency specifications for the troubled levothyroxine should be narrowed from 90-110% to 95-105%, committee members recommend.

Levothyroxine Potency Standards To Be Addressed By FDA Advisory Committees

FDA is focusing on potential “clinically significant concerns” and will address intraproduct issues before moving to questions of bioequivalence.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel